Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 70.48 USD 0.14% Market Closed
Market Cap: 41.6B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Edwards Lifesciences Corp
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Edwards Lifesciences Corp
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Total Other Income
$30.6m
CAGR 3-Years
187%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Total Other Income
-$27m
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Total Other Income
$60m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Total Other Income
-$302m
CAGR 3-Years
9%
CAGR 5-Years
2%
CAGR 10-Years
-14%
Abbott Laboratories
NYSE:ABT
Total Other Income
$358m
CAGR 3-Years
8%
CAGR 5-Years
14%
CAGR 10-Years
68%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
41.6B USD
Industry
Health Care

Edwards Lifesciences Corp., a leader in heart valve technologies and hemodynamic monitoring, has carved out a vital niche in the medical device industry. Founded in 1958 and based in Irvine, California, the company has consistently focused on innovative solutions to treat advanced cardiovascular diseases. Its flagship product, the transcatheter aortic valve replacement (TAVR), revolutionized how patients with severe aortic stenosis are treated, allowing doctors to perform minimally invasive procedures that significantly improve patient outcomes. As the global population ages and cardiovascular diseases become increasingly prevalent, Edwards is well-positioned to capitalize on this growing demand, with a robust pipeline of products aimed at addressing unmet medical needs. For investors, Edwards Lifesciences represents a compelling opportunity to tap into the expanding medical technology market. The company's strong financial performance, characterized by consistent revenue growth and impressive profit margins, highlights its effective execution and market leadership. Moreover, Edwards is committed to innovation, investing heavily in research and development, which not only fuels new product launches but also enhances its competitive edge. With a focus on long-term growth, expanding market presence, and a dedication to improving patient care, Edwards Lifesciences stands out as a promising investment for those looking to gain exposure to the dynamic healthcare sector.

EW Intrinsic Value
54.97 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Total Other Income?
Total Other Income
30.6m USD

Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Total Other Income amounts to 30.6m USD.

What is Edwards Lifesciences Corp's Total Other Income growth rate?
Total Other Income CAGR 3Y
187%

Over the last year, the Total Other Income growth was 419%. The average annual Total Other Income growth rates for Edwards Lifesciences Corp have been 187% over the past three years .

Back to Top